1. Cases-Amenos A, Martinez-Castelao A., Fort-Ros J, Bonal-Bastons J, Ruiz MP, Vallés-Prats M, Coll-Piera E, Galcerán-Gui JM, Investigadores del Estudio Micenas I. Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study. Nefrologia 2014; 34:189–198.
2. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23–33.
3. Li S, Zhou X, Zheng Y, Yi W. Effects of spleen-strengthening and kidney-invigorating prescription on nutritional status in rats with chronic renal failure. J Guangzhou U Tradit. Chin Med. 2003;20:230–2.
4. Pan X, Yang D, Li S, Yi W, Jianpi Yishen FB. Formula regulates the level of IL-1, IL-2 and IL-6 in patient with uremia. J Guangming. Chin Med. 2008;23:1122–3.
5. Garrido P, Ribeiro S, Fernandes J, Vala H, Rocha-Pereira P, Bronze-da-Rocha E, Belo L, Costa E, Santos-Silva A, Reis F. Resistance to recombinant human erythropoietin therapy in a rat model of chronic kidney disease associated anemia Int J Mol Sci. 2015:2015. https://doi.org/10.3390/ijms17010028 .